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Abstract
We have shown that inhibition of mTOR in granulosa cells and ovarian follicles results in compromised granulosa
proliferation and reduced follicle growth. Further analysis here using spontaneously immortalized rat granulosa cells has
revealed that mTOR pathway activity is enhanced during M-phase of the cell cycle. mTOR specific phosphorylation of p70S6
kinase and 4E-BP, and expression of Raptor are all enhanced during M-phase. The predominant effect of mTOR inhibition by
the specific inhibitor Rapamycin (RAP) was a dose-responsive arrest in the G1 cell cycle stage. The fraction of granulosa cells
that continued to divide in the presence of RAP exhibited a dose-dependent increase in aberrant mitotic figures known as
anaphase bridges. Strikingly, estradiol consistently decreased the incidence of aberrant mitotic figures. In mice treated with
RAP, the mitotic index was reduced compared to controls, and a similar increase in aberrant mitotic events was noted. RAP
injected during a superovulation regime resulted in a dose-dependent reduction in the numbers of eggs ovulated.
Implications for the real-time regulation of follicle growth and dominance, including the consequences of increased
numbers of aneuploid granulosa cells, are discussed.
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Introduction
Large scale clinical investigations have begun to reveal that
dietary and/or lifestyle choices can correlate with ovulatory
fertility [1–4]. Except for the striking example of functional
hypothalamic amenorrhea reported by Berga and colleagues [5,6],
mechanisms by which ‘environmental’ stressors and nutritional
status affect reproductive function have been elusive. Indeed, the
majority of anovular/amenorrhoeic patients suffer for occult
reasons. We hypothesize that the mammalian Target Of
Rapamycin) Serine/Threonine kinase (mTOR) is a conserved,
critical factor in the production of ‘healthy’ eggs capable of giving
rise to offspring.
mTOR acts to integrate signals from mitogens, stress, and
available nutrition [7,8]. During periods of compromised nutrition
(decreased available amino acids or sugars), growth factor
withdrawal, or stress, mTOR activity is decreased. This leads to
reduced cell proliferation [9] and tissue growth [10], and the onset
of autophagy [11]. mTOR functions as part of at least two multi-
protein complexes, each of which has defined roles in the control
of cell growth.
The first TOR complex, the mammalian TOR complex 1
(mTORC1) consists of mTOR and cofactor proteins including
Raptor [12–14]. The other complex, mTORC2, includes the
cofactor Rictor in place of Raptor [15,16]. mTORC2 has been
shown to regulate the organization of the actin cytoskeleton, acting
through Rho GTPases [15,17]. The namesake inhibitor Rapamy-
cin (RAP) mimics the effects of cell stress or nutrient starvation by
blocking mTOR directly after binding an intracellular receptor,
FKBP12. The FKBP12-RAP complex was originally thought to
only inhibit mTORC1 signaling [18], however, inhibitory effects
on mTORC2 have been uncovered [19–21], suggesting that
metabolic and cytoskeletal regulation by mTOR are tightly
integrated.
mTOR controls the initiation of protein translation. Under non-
stressed conditions, mTOR phosphorylates p70 S6 kinase
(p70S6K) and eukaryotic translation initiation factor 4E-binding
protein 1 (4E-BP1). A lack of mTOR phosphorylation of p70S6K
results in reduced downstream action upon the 40S ribosomal
protein S6 and eIF4B, each of which recruit ribosomes to the 59
end of an mRNA [22]. In 2004, Alam et al. [7] showed that
p70S6K phosphorylation in primary rat granulosa cells is
dependent on mTOR activity, confirming that this part of the
pathway is intact in granulosa cells. 4E-BP1 is a translational
repressor that acts by binding the eIF4E translation initiation
factor. Phosphorylation of 4E-BP1 by mTOR disrupts this
interaction, freeing eIF4E to initiate cap-dependent translation
[23,24].
Endocrine, paracrine, and autocrine signaling all converge on
granulosa cells, controlling their growth and differentiation
[7,25,26]. We have shown that mTOR inhibition in primary
mouse granulosa cells and follicles results in reduced granulosa cell
proliferation in vitro [8]. Using the Drosophila model system, we
have also detected specific effects upon ovarian function in vivo.I n
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oogenesis, effectively sterilizing females [27] (see [28] for a review).
However, it remained to be seen whether inhibition of mTOR in
vivo in mammals would affect ovarian function.
Here, we took advantage of the the convenient spontaneously
immortalized rat granulosa cell line (SIGC) [29]. SIGC were
originally derived by culturing BD IV rat granulosa cells from
punctured follicles in vitro, and isolating those cells that continued to
proliferate after approximately 13 passages (instead of luteinizing).
Banu et al. [30] performed a detailed gene expression analysis of the
cells, showing that the cells maintained a granulosa identity
(expressing Estrogen Receptor-a and -b, Follicle Stimulating
Hormone Receptor, Luteinizing Hormone Receptor, Steroidogenic
Factor-1, and other functional markers of granulosa cells).
Interestingly, the group that originally established SIGC lines found
that while in early passages, the cells were almost uniformly diploid,
after extended passages, the cells became tetraploid [29].
mTOR’s action during proliferation was originally thought to be
limited to the mitogen-sensitive G1 stage [31,32] of the cell cycle.
However, evidence is building for M-phase specific roles for mTOR
signaling [8,33]. Indeed, an autophosphorylated form of mTOR
has been localized to midzone microtubules and the midbody of the
mitotic apparatus in cancer cells [34]. In the studies presented here,
preliminary examination showed that expression of mTOR
signaling pathway molecules in SIGC was similar to that seen in
mouse granulosa cells in vivo, including during M-phase. We thus
used the cell line to evaluate the effects of mTOR inhibition upon
proliferation, cell cycle stages, and mitotic events. To determine the
effects of mTOR inhibition in vivo, mouse follicle development and
ovulation were measured in the presence and absence of RAP.
Results
mTOR signaling molecule expression is conserved in
spontaneously immortalized rat granulosa cells
First, we asked whether the expression of mTOR signaling
molecules was conserved between mouse ovary, primary mouse
granulosa cells [8], and SIGC (Fig. 1). We extended our studies to
include the cofactor Raptor and two downstream mTOR kinase
targets, p70S6 kinase and 4E-BP. Care was taken to evaluate
mTOR signaling molecule expression during interphase and
during the individual stages of M-phase. As in mouse granulosa
cells, mTOR is expressed at consistent levels in the cytoplasm in
SIGC (red, Fig. 1A; compare to no-first-antibody control shown in
1B). Again as seen in mouse granulosa cells, Serine 2448-
phosphorylated mTOR (P-mTOR) is very highly expressed during
the mitotic G2/M cell cycle stage(s) (expression during metaphase
of mitosis shown in Fig. 1C and 1C9; see Fig. S1 for representative
expression from late G2/prometaphase through telophase). This
phosphorylation of mTOR at Serine 2448 has been shown to
correlate with mTOR kinase activity [35–37]. Co-staining for a-
tubulin and P-mTOR revealed that the phosphoprotein was
highly enriched in the region of the mitotic spindle (1C9).
Raptor, the cofactor required for RAP-sensitive mTORC1
kinase activity, was also expressed at high levels in SIGC during
mitosis, also in the region of the mitotic spindle (Fig. 1D, 1D9
shows co-localization with the mitotic apparatus). After detecting
both P-mTOR and Raptor in this region, we sought to determine
whether known downstream mTOR kinase substrates might be
upregulated during mitosis, potentially in the region of the mitotic
spindle. Both phospho Threonine 389 p70 s6 kinase (P-p70S6K,
red channel, Figs. 1E, F) and phospho Threonine 37/46 4E-BP (P-
4E-BP, red, Figs. 1G, G9) were enhanced in mitotic cells. As with
P-mTOR and Raptor, P-p70S6K was enriched in the region of
the mitotic spindle adjacent to metaphase chromosomes in these
granulosa cells (1E, cell in oval shown in magnified inset, a-tubulin
staining omitted to highlight narrow bands of P-p70S6K
expression-red, denoted by yellow arrows, adjacent to chromo-
somes-blue). P-p70S6K was also expressed at high levels in a
subset of SIGC in interphase (1E, green arrows). In 1F, an early
anaphase cell is shown, where P-p70S6K remains expressed at
high levels in the region of the mitotic spindle. The expression of
P-4E-BP was enhanced during mitosis (arrows, green arrow-cell in
prometaphase, yellow, metaphase, G9 shows staining of P-4E-BP
Figure 1. Expression of mTOR signaling molecules in Rat SIGC. Compared to total mTOR (A), phospho-Ser2448 mTOR (C,C9) is upregulated
during M-phase (see also Fig. S1). Cells processed identically except for omitted first antibody are shown in (B). Raptor (D) is expressed at higher levels
during mitosis relative to neighboring interphase cells. Phosphorylation of the downstream mTOR substrates phospho-Thr 389 p70S6K (E,F), and
phospho-Thr 37/46 4E-BP (G) is also enriched during mitosis. P-p70S6K in particular is localized to regions adjacent to chromosomes (E, dashed oval
and inset, yellow arrows). Phospho-p70S6K was also enriched in approximately 1% of interphase cells (E, green arrows). Co-staining with a-tubulin
reveals that P-mTOR (C9), Raptor (D9), and P-4E-BP (G9) are present at high levels in the region of the mitotic spindle.
doi:10.1371/journal.pone.0021415.g001
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spindle and throughout cells was found (G9). Overall, the
expression of mTOR was found to be similar to that seen in
granulosa cells of the mouse ovary, and the expression of signaling
pathway members and substrates suggested a targeting of this
pathway to the mitotic spindle in SIGC.
Comparison of ‘active’ P-mTOR and cells that express high
levels of Raptor and the substrates suggest a high degree of overlap
within the cell cycle, specifically within M-phase. While P-mTOR
is present at high levels between late G2 (early stages of
chromosome condensation) and mitotic telophase, Raptor has a
tighter window of expression (1D and Fig. S1). High Raptor
expression begins during late G2 and ends at approximately
mitotic anaphase. This can be seen by comparing the entirely
consistent expression of P-mTOR during anaphase (Fig. S1A,
yellow arrows) and beyond to cytokinesis (Fig. S1A, yellow
arrowhead) with Raptor, the expression of which is inconsistent
during anaphase (Fig. S1B, compare anaphase mitotic figure at
yellow arrow with those marked by white arrowheads) and is not
seen during late anaphase/telopase/cytokinesis. This rapid
disappearance of Raptor is suggestive of regulated degradation
during and after mitosis and warrants further study. The mTOR
substrates P-Ser p70S6K and P-Thr 37/46 also showed enriched
expression between late G2 and anaphase. The only exception to
the overlap of expression of mTOR, Raptor, and the substrates,
was an interesting, strong predominantly cytoplasmic expression
seen in approximately 1% of interphase SIGC (Fig. 1G, green
arrowhead). The conserved expression patterns relative to the
mouse [8] supported the use of the SIGC cells as a model for
studies of mTOR function during granulosa survival, mitosis, and
proliferation.
mTOR inhibition results in altered granulosa cell
proliferation
Prior to testing the effects of mTOR inhibition upon SIGC
proliferation, we confirmed that RAP indeed inhibited kinase
activity in these cells. We treated SIGC with a concentration series
of RAP and assessed the expression of P-p70S6 kinase (Thr 389)
and P-4E-BP (Thr 37/46) by Western blot (Fig. 2A,B). SIGC cells
were either treated with ethanol vehicle, 0.1 nM RAP, or 10 nM
RAP for 18 hours. mTOR inhibition was confirmed as P-p70S6K
(2A) and P-4E-BP (2B) were each significantly reduced, in
respective dose-dependent fashions (graphed as a ratio of target
band density to beta actin loading control band density) in the
presence of RAP.
We then assessed cell number (Fig. 2C) directly and indirectly
(via biochemical assay, Fig. 2D) 18 and 48 hours post-treatment
with either ethanol vehicle or a concentration series of RAP. As
cell death was not induced at any concentration of RAP used, the
cell ‘viability’ assays measured relative cell proliferation rates and
were not reflective of cells lost to toxicity. A biphasic response was
seen across the concentration series. That is, higher concentrations
of RAP (100 and 1000 nM) resulted in significantly reduced
proliferation at 18 and 48 hours versus controls, and, low
concentrations (here, 1E-3 and 1E-5 nM) of RAP resulted in
increased proliferation versus vehicle. The mitogenic effect of low
RAP was reminiscent of the effects seen on cultured mouse follicles
in our previous study [8].
Next, we tested whether long term exposure to RAP was
required for the effects upon SIGC proliferation. We treated SIGC
with identical concentrations of the drug, washing it out after
3 hours, and again measured cell viability at 18 and 48 hours post-
treatment onset. The effects of transient exposure are summarized
in Figure 2E. Here, the overall effects of mTOR inhibition were
lessened from that of constant treatment, but significant declines in
viability were again found after treatment with the two highest
doses of RAP. Interestingly, the increased cell proliferation and
viability seen in cells with constant low levels of RAP (Fig. 2C,D)
were not seen when the drug was washed out. This suggests that
the mitogenic effect of low RAP requires longer, if not constant,
exposure. Overall, mTOR inhibition resulted in striking effects
upon granulosa cell proliferation and population size.
mTOR inhibition alters granulosa cell cycle parameters
When inhibited by physiological cell stressors or by pharmaco-
logical means, mTOR inhibition has been shown by other groups
to result in decreased proliferation mainly by inducing cell cycle
arrest in the G1 stage. It should be noted that inhibition of mTOR
during interphase would be responsible for arrest in G1, and thus the
interphase expression patterns of P-mTOR, Raptor, P-p70S6K,
and P-4EBP (Fig. 1) should not be ignored. Consistent with this,
cell cycle analysis of SIGC by flow cytometry showed that
significantly greater percentages of cells were present in the G1
fraction (Fig. 2F) in the presence of high RAP (approximately
55%), while lower percentages of cells were in G1 when low RAP
or vehicle was present (approximately 25%). Not all cells were
arrested in G1 in any treatment, that is, a fraction of cells always
continued to divide. We confirmed the presence of actively mitotic
cells by performing live-cell video measurements, which revealed
that no significant difference between the length of time taken in
mitosis (from ‘rounding up/prometaphase’ to complete cytokine-
sis) resulted from any treatment (Kasiman, Yu, and Johnson,
unpublished). Interestingly, video microscopic observation of
karyokinesis and cytokinesis revealed a fraction of cells whose
chromosomes appeared ‘‘trapped’’ within the region of cell
division, a feature that we later assessed in detail (below).
Cell death is not induced by mTOR inhibition
In order to characterize the growth dynamics of SIGC cultures,
we completed a number of concurrent studies to test whether cell
death was being induced by RAP treatment. Gross hallmarks of
cell death (e.g., lack of overt DNA condensation and blebbing)
were absent from any cells processed for direct cell counts, viability
measurements, and flow cytometry (2F), even when the super-
physiological dose, 1000 nM RAP, was applied. We stained SIGC
with Annexin V/Propidium iodide (data not shown) and
performed biochemical caspase assays (Fig. 2G) to test for the
induction cell death. In sum, these experiments confirmed that
neither apoptosis nor necrosis resulted from any dose of RAP used.
Due to the detection of mTOR signaling pathway molecules in the
region of the mitotic spindle (Fig. 1) and the video microscopic
observation that mitotic anomalies seemed to follow RAP
treatment, we went on to carefully characterize mitotic figures in
treated versus control cells.
Anaphase bridges are consistently induced by mTOR
inhibition; estradiol consistently decreases the
percentage of anaphase bridges
As shown, despite the overall growth curves, consistent fractions
of cells continue to divide in the presence of even the highest
concentrations of RAP used. The only detectable difference
between treated and untreated cells was an apparent increase in
mitotic abnormalities in treated cells. This caused us to ask
whether such abnormalities were being induced by mTOR
inhibition. We hypothesized that the population of cells that
continues to grow in the presence of RAP would experience
abnormalities in mTOR signaling during mitosis and potentially,
mTOR and Ovarian Follicle Growth
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We went on to directly assess those continuing mitotic events
(Fig. 3).
Assessment of mitotic figures in treated versus control cells was
performed by staining cells with DAPI and mitosis-specific
Phospho-Histone H3 (Ser10, denoted PHH3) (example of normal
mitotic figures shown in Figure 3A9). While DAPI staining alone
was sufficient for revealing the majority of bridges, PHH3 staining
generally increased contrast (see electronically amplified DNA
signal in Fig. 3A0, denoted by *, versus overlay) and made their
characterization faster. This analysis revealed a surprisingly high
representation of mitotic anomalies referred to as anaphase
bridges [38], even in untreated cells. Anaphase bridges result
where one or more pairs of sister chromatids fail to disjoin during
mitosis and a strand of chromosome is trapped in the region of
cytokinesis. The ultimate fate of most such bridges, if not resolved,
is the degradation of the DNA within and thus the development of
chromosomal aneuploidy. After 18 hours of treatment, we
counted a minimum of four fields of 100 mitotic figures per
treatment. This revealed that the defined mitotic abnormalities
known as anaphase bridges and lagging chromosomes were indeed
induced by treatment with RAP (percent abnormal anaphase/
telophase anaphase bridges shown in Fig. 3B), in a dose-responsive
manner.
Treatment with 0.1 and 100 nM RAP resulted in significantly
(*, Pv0.001) higher percent abnormal A/T mitotic figures than
vehicle treatment. When considering the rates of aneuploid
granulosa cells found in growing follicles, it is striking that
dominant follicles have been shown to have fewer aneuploid
granulosa cells [39–41]. As high estradiol production is also a
feature of the dominant follicle, we hypothesized that estradiol
would counter the induction of aberrant mitotic figures by RAP.
When estradiol was included in cultures at 10 ng/ml (to
approximate intrafollicular estradiol), the percent of abnormal
anaphase/telophase figures versus corresponding RAP-only treat-
ments was significantly reduced ({,P v0.05). Interestingly, the
inclusion of this concentration of estradiol slightly but insignifi-
cantly reduced the percent abnormal mitotic figures seen in
vehicle treated cells in a manner that was countered by the
addition of 100 nM ICI182780 estradiol receptor antagonist.
Overall, these data prompted us to test whether similar effects of
mTOR inhibition upon granulosa cell mitosis result within
growing follicles in vivo.
Mitotic abnormalities arise in vivo in response to mTOR
inhibition
In order to test whether mitotic abnormalities arise in vivo in
follicles, we injected 8 week-old female mice on two consecutive
Figure 3. Mitotic errors and chromosomal aneuploidies are
induced by RAP in a dose-dependent fashion; Estradiol
consistently reduces mitotic anomalies. SIGC for were grown for
18 hours in the presence or absence of RAP, and then were fixed and
stained with DAPI (red) and optionally the mitosis-specific Phospho
Histone H3 Ser10 chromatin modification (PHH3, green) using a
fluorophore-conjugated antibody. Representative staining is shown in
A9, and a ‘normal’ anaphase/telophase mitotic figure where chromo-
some segregation has occurred entirely is highlighted (encircled by
oval). An abnormal mitotic figure demonstrating an anaphase bridge is
shown in A0 (* denotes higher magnification inset where DNA signal
has been amplified electronically at top right to completely reveal DNA
bridge, PHH3 and merged images below). Abnormal anaphase/
telophase mitotic figures were counted and the percent found per
treatment are summarized in B. RAP was found to increase abnormal
mitotic figures in a dose-dependent fashion, and significant increases
were found at 0.1 and 100 nM drug (*, Pv0.001 vs. vehicle-only (VEH)
controls). Concurrent treatment with 10 ng/ml estradiol significantly
reduced abnormal mitotic figures, { Pv0.05, versus their individual
corresponding RAP-only treatments.
doi:10.1371/journal.pone.0021415.g003
Figure 2. mTOR inhibition by RAP in Rat SIGC. Treatment with RAP is shown to inhibit mTOR activity by reducing phosphorylation of the target
residue of p70S6 kinase (A) and 4E-BP (B). As low as 0.1 nM RAP significantly (Pv0.05, one-way ANOVA, letters denote bars that significantly differ
from one another) reduces P-p70S6K and P-4E-BP eighteen hours after treatment. Cells were similarly treated with a dose curve of RAP (C–E) and
were counted (C) or processed for biochemical viability assay (D) at 18 and 48 hours post-treatment. High doses (100 and 1000 nM) of the drug
resulted in significantly (Pv0.0001, one way ANOVA with Bonferroni’s Multiple Comparison Test, denoted a, b) reduced cell number and viability at
48 hours compared to all other treatments (denoted by a,b). Low doses (1E-3 and 1E-5 nM) of RAP resulted in non-significant but consistently
increased cell number at 18 and 48 hours. Washout of RAP after 3 hours of treatment resulted in reduced, but still significant reductions in cell
viability 48 hours post-treatment (E). Altered SIGC proliferation correlated with altered cell cycle parameters (F). Cells were grown in the dose curve of
RAP. 18 hours post-treatment, cells were fixed and processed for DNA content cell cycle analysis via flow cytometry. Average results from three
individual experiments are shown in F. As seen in other cell types, a dose-responsive induction of cells in the G1 stage of the cell cycle occurred with
RAP treatment. Significantly different percentages of cells in G1 were found (Pv0.05, one way ANOVA with Bonferroni’s Multiple Comparison Test,
significantly different populations denoted by a,b,c) with increasing RAP. (G) RAP does not induce Caspase activity in Rat SIGC. SIGC were treated with
either vehicle (VEH) or specified concentrations of RAP or Camptothecin (CT - positive control for apoptosis induction). Cells were collected at 24 and
48 hours post-treatment and processed for plate based chemiluminescent Caspase activity measurements. Relative Luminescence units are graphed
for each sample per time point. Data shown are the average of two unique experiments.
doi:10.1371/journal.pone.0021415.g002
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Histological preparations were made from the ovaries and
granulosa mitotic figures were counted within individual follicles
from ‘end to end. ’ Fig. 4A shows results from counts of granulosa
cell mitotic figures are shown along with examples of mitotic
figures (Fig. 4B). As seen in SIGC treated in vitro, granulosa cells in
follicles demonstrate a dose-responsive increase in abnormal
anaphase-telophase mitotic figures in treated animals versus
vehicle. Detecting this same effect in vivo supported the use of
SIGC to approximate these processes and also suggests that the
mitotic errors detected are likely to arise through similar processes
as seen in the cell line. Even so, the use of RAP raised the
possibility that broader non-physiological or toxic effects could
result, inducing follicle atresia in vivo, perhaps even affecting the
‘primordial reserve’ of oocytes. We went on to assess this directly.
Follicle reserve is unaffected by in vivo mTOR inhibition;
RAP reduces ovulation in a dose-responsive manner
To determine whether mTOR inhibition using systemic RAP
delivery affected follicle health in mice, we used a direct
histological approach [42,43]. We found that numbers of healthy
follicles were not affected by RAP delivery versus vehicle (Fig. 5A).
RAP treatment thus does not result in detectable follicle loss via
atresia. However, the numbers of ovulated eggs were reduced in a
dose-responsive manner when RAP was included in a ‘superovu-
lation’ regime (Fig. 5B, see Fig. S2 for injection regime). Significant
differences (Pv0.05) were seen between groups treated with 4
doses of vehicle, 5 mg/kg, or 50 mg/kg body weight. No
difference in the number of eggs with fragmented or ‘unhealthy’
appearance was seen in RAP treated animals in these experiments:
ovulated eggs were predominantly of ‘healthy’ appearance.
Finally, we tested whether oocyte quality is compromised when
animals were treated with four 5 mg/kg doses of RAP versus those
treated with vehicle (treatment scheme summarized in Figure S2).
Here, we fertilized eggs from each group in vitro and monitored
their development to blastocyst. Table 1. summarizes the results
from these experiments. Three animals either received the same
5 mg/kg regimen of RAP or vehicle during superovulation and
eggs were again collected. Data is presented individually for
animals treated with RAP, with the average number of healthy-
appearing eggs and the number and percent that developed to
blastocyst after in vitro fertilization. As shown, while animals treated
Figure 4. Mitotic errors are induced in granulosa cells of large preantral follicles by systemic RAP treatment in mice. Histological
preparations of adult C57Bl/6 ovaries (n=3 mice per treatment) collected 24 hours after the second of two RAP injections were analyzed for the total
number of normal versus abnormal mitotic figures (A) in 5 follicles that contained between 10 and 15 granulosa cell layers. Significant differences
were seen in both normal A/T mitotic figures (black bars denoted a,b,c; Pv0.005, one way ANOVA with Bonferroni’s Multiple Comparison Test) and
abnormal figures (i,ii,iii). Examples of abnormal mitotic figures are shown in (B), where a normal A/T metaphase mitotic figure can be seen (yellow
arrowhead) near a mitotic figure displaying a lagging chromosome (three red arrowheads denote anaphase chromosomes and lagging central
chromatin). A representative anaphase bridge is shown at right.
doi:10.1371/journal.pone.0021415.g004
Figure 5. mTOR inhibition does not impact the primordial reserve of oocytes but does inhibit ovulation. Adult C57Bl/6 females were
dosed with either vehicle or 4 daily does with 50 mg/kg b.w. RAP. Healthy follicles were counted in histological preparations of ovaries, results are
summarized in A. No significant difference was found in either primordial follicles, or, growing preantral or antral follicles. Separately, adult animals
recieved either 4 doses of vehicle or RAP beginning on day 1 of a superovulation regime. On day 4, ovulated eggs were collected, and their numbers
are summarized in B.
doi:10.1371/journal.pone.0021415.g005
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fraction of eggs with a healthy appearance and the percent that
developed to blastocyst did not significantly differ from that of
vehicle-treated animals. Thus mTOR inhibition with this dose
resulted in reduced ovulation but little if any deleterious effect
upon those oocytes that did ovulate.
Discussion
In summary, mTOR inhibition resulted in reduced granulosa
cell proliferation in the absence of an induction of cell death. This
reduced proliferation results from an increased number of cells in
the G1 stage of the cell cycle. Our data are consistent with reports
showing that mTOR is involved in cell cycle progression at G1
[31,32]. Some of the effects of mTOR inhibition on SIGC
proliferation here can be seen occurring within the G2/M stage(s)
of the cell cycle (Figs. 2, 3, 4). This outcome correlates with the
detection of mTOR pathway molecules in the region of the mitotic
apparatus [8,33]. We have additionally detected increased
fractions of cells that undergo anomalous mitotic events during
mTOR inhibition.
As seen previously in vivo in the mouse ovary and in vitro in
cultured primary mouse granulosa cells [8], the mTOR pathway
appears to be upregulated during M-phase of the cell cycle. Here,
SIGC cells were found to exhibit the same upregulation of Ser
248-phosphorylated mTOR, and also enhanced phosphorylation
of the downstream targets p70S6 kinase and 4E-BP. Both mTOR
targets demonstrated markedly enhanced expression near and
around mitotic chromosomes. Interestingly, the mTORC1
cofactor Raptor appears to also be upregulated during M-phase.
As we performed staining for the total protein (and not a
phosphoprotein), it may be that the expression or stability of
Raptor protein is altered before and during M-phase. Raptor also
was found to be enhanced in the region of the mitotic spindle in
SIGC cells. The recent finding that Raptor is phosphorylated by
cdc2 prior to and during M-phase may be related to this [33]
enhancement. Overall, enhanced mTOR complex and phospho-
protein targets, were found to be consistently higher in M-phase
than during interphase.
The effects of RAP treatment of mice in vivo are consistent with
effects on follicle growth to ovulatory stages. RAP treatment did
not result in detectable effects on the pool of primordial follicles,
nor upon the number of growing preantral follicles. However, the
number of antral follicles was slightly reduced compared to
vehicle-treated animals, and this corresponded to a reduction in
the number of ovulated eggs. While compromised follicle
development to ovulation might have also resulted in deleterious
effects upon the eggs that were ovulated in the presence of RAP,
the fraction of eggs that developed to blastocyst after fertilization
was unchanged compared to vehicle.
The in vivo delivery of RAP may be acting at multiple levels in the
mouse to limit the growth of maturing follicles. It is possible that
mTOR inhibition in the hypothalamus or pituitary could lessen the
production of gonadotrophin hormones, contributing the the effects
within the ovary. However, our previous data showing that
treatment of mouse follicles in vitro with RAP results in growth
retardation [8] supports direct effects at the level of ovarian follicles.
Because of this, mTOR’s action in vivo in the ovarian follicle is
supported as an important positive regulator of follicle growth and
development. mTOR inhibition appears to slow the growth of the
follicle in two ways: increased cell cycle arrest in the G1 stage of the
cell cycle (as previously seen in several different cell types), and via
the induction of mitotic anomalies in granulosa cells.
Those granulosa cells that continued to divide in the presence of
high RAP are increasingly susceptible to mitotic abnormalities
including anaphase bridges. Anaphase bridges arise where one or
more pairs of sister chromatids fail to disjoin during mitosis and a
strand of chromosome is ‘trapped’ in the region of cytokinesis. The
fate of most such bridges, if not resolved, is the degradation of the
DNA within and thus the development of chromosomal
aneuploidy [44]. Anaphase bridges have been shown to arise
from several defined mechanisms, most often involving a lack of
proper telomere maintenance [38] sometimes involving topoisom-
erase function [45] or, helicase [46] function. Two publications
from the same group offer evidence that RAP treatment can lead
to chromosomal non-disjunction during M-phase in yeast and
mammalian cell cultures [47,48]. Strikingly, estradiol treatment
consistently decreased anaphase bridges in mitotic SIGC versus cells
treated with the corresponding concentration of RAP alone. Since
estradiol can counter the effects of RAP, we propose that both the
cell cycle effects and the induction of mitotic anomalies act to
control the rate of follicle growth directly and may be related to
the selection and maintenance of the dominant follicle (below).
It has been reported that growing follicles in a variety of
mammalian species contain high proportions of aneuploid
granulosa cells [39,40]. The largest (dominant) follicles are a
notable exception, as those appear to be nearly uniformly euploid
[41]. Since the dominant follicle itself produces high levels of
estradiol (likely the highest levels relative to subordinate follicles)
[49,49–54], it is possible that mTOR is involved in the process of
dominant follicle selection in this fashion. These data in sum
further support the TOR pathway as a crucial factor in the control
of the production of fertilizable eggs.
Materials and Methods
Mice/Ethics Statement
The studies included in this work were performed in accordance
with the Yale University Institutional Animal Care and Use
Committee Policies for Animal Use under an approved animal
protocol (#2005-10990). Handling and euthanasia of mice were
performed per the National Institutes of Health Guide for the
Care and Use of Laboratory Animals. 8-week old C57BL/6 mice
were used for these studies.
Cells/cell culture
SIGC cells were maintained in DMEM/F12 with 10% serum,
with 16 Penicillin/Streptomycin. 50000 cells per well were
Table 1. mTOR inhibition suppresses ovulation but does not
affect subsequent embryo development.
Animal
Healthy Oocytes
Ovulated
Number of Healthy
Eggs Per Mouse
(Unhealthy)
that Developed
to Blastocyst (%)
1 6 (3) 5 (83%)
2 11 (1) 7 (64%)
3 7 (5) 5 (71%)
Average RAP Tx 8 (3) 5.7+0.7 (72.7+5.5%)
Average VEH Tx 20.3 (4) 16.1 (80+5.2%)
Groups of three 8-week old mice were injected with 4 doses of RAP or ethanol
vehicle (VEH) during a superovulation regime. Eggs were collected and their
appearance was evaluated (‘healthy’ or ‘unhealthy’). Healthy eggs were
subjected to in vitro fertilization and development to blastocyst was scored.
doi:10.1371/journal.pone.0021415.t001
mTOR and Ovarian Follicle Growth
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e21415plated in 96-well plates. Cell viability was assessed via the
CellTiter96 assay (Promega) at 7 hour intervals after the addition
of RAP (LC Laboratories), estradiol, or corresponding vehicle
volumes of ethanol. 10 ng/ml estradiol was used to mimic
intrafollicular concentration after [55]. Where indicated, the
estradiol receptor antagonist compound ICI 182780 (Tocris
Bioscience). For direct counts of mitotic figures, cells were plated
in 8-well culture chambers and treated identically with RAP or
vehicle. 21 hours after treatment, cells were labeled with either
DAPI or TO-PRO-3 and visualized after image capture at 1006
magnification.
Immunostaining
Cells grown in slide chambers were fixed, washed, and blocked
in antibody buffer: Tris-Buffered Saline containing 0.1% Tween-
20, 5% normal goat serum, and 0.01% Tween-20 then incubated
with rabbit anti-mTOR, anti-P-mTOR, anti-Raptor, anti-phos-
pho Thr 37/46 4E-BP (each from Cell Signaling Technology, Inc.
#’s #2983, #2971, #4978, and #2855, respectively, and diluted
1:300), or anti phospho Thr389 p70S66 kinase (Sigma, #S6311)
overnight at 40C. Cells were then washed 3 times for 10 minutes,
and stained with anti-rabbit second antibody (Alexa 546-
conjugate, Molecular Probes). Cells were optionally co-stained
with Alexa 488-conjugated anti a-tubulin or anti-phospho Histone
H3 (Molecular Probes). Cells were then washed with PBS 3 times
for 5 minutes, and cell nuclei were stained by including DAPI in
the second PBS wash. Cells were coverslipped in Crystal Mount
mounting media. Images were captured using a Zeiss Axioplan 2
epifluorescence microscope, an in-line digital camera, and
Axiovision imaging software.
Western blot analysis
For analysis of intracellular proteins, cells were lysed using 1%
NP40 and 0.1% SDS in the presence of protease and phosphatase
inhibitors. Protein concentrations were calculated by BCA assay
(Pierce Biotechnology, Rockford, IL). Proteins were then diluted
with gel loading buffer to 20 mg and boiled for 5 min. Proteins
were resolved under reducing conditions on either 10 or 12%
SDS-PAGE gels and then transferred onto nitrocellulose mem-
branes (NEN Life Sciences, Boston, MA). Membranes were
blocked in 5% powdered milk in PBS/0.05% Tween 20 (PBS-T),
then washed and incubated overnight at 40C with anti-Phospho-
Ser 2448 mTOR or anti-Phospho-Thr389 p70S6K in PBS-T/1%
milk. After washing, second antibody conjugated to peroxidase
(Vector Laboratories) in PBS-T/1% milk was applied and signal
detected by enhanced chemiluminescence (NEN Life Sciences). All
experiments were repeated at least three times, and the intensity of
the signals was analyzed using a digital imaging analysis system
and 1D Image Analysis Software (Scientific Imaging Kodak
Company). b-actin (mouse ant-ib-actin, Sigma) was used as
internal control.
Cell counts and cell viability/apoptosis analysis
5000 cells were grown in wells of a 12-well plate as above with
either ethanol vehicle, or the specified concentration of RAP and/
or estradiol in triplicate. At the end of culture periods, cells were
trypsinized, and resuspended in 100 ul of PBS containing 0.01%
Trypan Blue (EMD Chemicals); the number of cells was
determined using a hemocytometer by counting those cells that
excluded Trypan Blue. Cell viability (and indirectly, cell death,)
was assessed using the CellTiter assay [56,57] 18, 24, or 48 hours
after the addition of vehicle or RAP. Caspase activity was
measured using Caspase-GLO assays per [58].
Flow cytometric cell cycle analysis
For flow cytometric analysis, cells were grown in the indicated
conditions, fixed in 70% Ethanol, and stained with Propidium
iodide per standard protocols. Sample runs and analyses were
performed using a FACScan cytometer in the Yale FACS facility,
Section of Immunobiology, Department of Internal Medicine and
Yale Cancer Center.
Ovulation assessment, histomorphometric analysis of
mitotic figures, and in vitro fertilization
For in vivo studies, 8 week old C57Bl/6 animals were injected
intraperitoneally with the indicated doses of RAP or vehicle as
follows during a ‘superovulation regime’ and ovaries were isolated.
Injections of RAP (5 or 50 mg/kg body weight) or vehicle were
given over two days. On Day 1, 5 IU PMSG was administered in
the afternoon. Two drug or vehicle doses followed on Day 2 and
Day 3; 5 IU hCG was injected into animals the afternoon of Day
3. The morning of predicted ovulation (14 hours post-hCG),
animals were killed and oocytes were flushed from oviducts and
counted. Where indicated, in vitro fertilization studies were
performed per Hogan et al, 1994. Briefly, the morning of egg
collection, a male C57Bl/6 animal was killed and capacitated
sperm was added to collected eggs. The determination of
anaphase/telophase mitotic configuration in growing mouse
ovarian follicles was performed as follows: three large early antral
follicles with no visible apoptotic granulosa cells were selected at
random in three unique ovaries; mitotic figures were counted from
end-to-end in serial sections of each follicle. Ovaries were fixed in
Dietrich’s fixative, stained with Weigert’s Iron Hematoxylin and
Picric acid/Methyl Blue and mounted on glass slides. All samples
were counted blindly, on coded slides [42].
Statistical analyses
All statistical analyses were performed using the GraphPad
Prism 4 statistical package (GraphPad Software, Inc.). Mean data
is presented for each set of replicates (number of replicates per trial
is indicated for each experiment), and error bars represent the
SEM. One-way ANOVA analysis was performed upon densito-
metric data from Western blots, and two-way ANOVA was
performed upon data from biochemical viability, cell number, and
anaphase bridge quantitation experiments. P values are listed per
experiment to denote statistical significance.
Supporting Information
Figure S1 P-Ser 2448 mTOR and Raptor exhibit over-
lapping expression in SIGC during mitosis. Immunofluo-
rescence detection of P-mTOR (A) and Raptor (B) in SIGC show
that the phosphoprotein and mTORC1 cofactor are each present
at high levels during mitosis. While P-mTOR is present at high
levels between late G2/early prometaphase (A, green arrow) and
late telophase/nearly complete cytokinesis (A, yellow arrowhead),
Raptor protein is at high levels between late G2/prometaphase (B,
green arrow) and approximately anaphase. Some anaphase cells
show high Raptor expression (dual yellow arrowheads, compare to
P-mTOR in A) while other cells show lower Raptor expression
(white arrowheads).
(TIF)
Figure S2 Scheme of superovulation. 8-week old mice
received gonadotrophin- containing preparations (PMSG and
hCG) and either RAP or VEH, after which eggs were collected,
evaluated, and subjected to in vitro fertilization.
(TIF)
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